Quince Therapeutics (NASDAQ:IRLA) Posts Quarterly Earnings Results

Quince Therapeutics (NASDAQ:IRLA) issued its earnings results on Friday. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.28), Zacks reports.

Quince Therapeutics Trading Up 0.1%

IRLA traded up $0.02 on Friday, hitting $39.80. The company had a trading volume of 55,375 shares, compared to its average volume of 183,078. Quince Therapeutics has a 12-month low of $15.10 and a 12-month high of $909.98. The firm has a market cap of $40.60 million, a P/E ratio of -0.25 and a beta of 1.78.

Analyst Ratings Changes

IRLA has been the topic of a number of research reports. Weiss Ratings started coverage on Quince Therapeutics in a research note on Tuesday, October 13th. They issued a “sell (d-)” rating on the stock. Raymond James Financial upgraded shares of Quince Therapeutics to a “moderate buy” rating in a research report on Friday, October 9th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold”.

About Quince Therapeutics

Quince Therapeutics, Inc. is a clinical-stage biotechnology company developing therapies for rare diseases and other conditions with significant unmet medical needs. The company’s technology platform is designed to use patients’ own red blood cells to deliver therapeutic compounds, with the goal of providing sustained treatment while limiting systemic exposure. Quince’s lead program is the EryDex System, an investigational treatment that loads dexamethasone sodium phosphate into a patient’s red blood cells for controlled release.